US · INSM
Insmed Incorporated
- Sector
- Healthcare · Biotechnology
- Headquarters
- Bridgewater, NJ 08807
- Website
- insmed.com
Price · as of 2025-12-31
$133.26
Market cap 31.85B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $74.03 | -44.45% |
| Intrinsic Value(DCF) | $5,263.35 | +3,849.68% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $3.96 | $18.44 | $3.95 | $0.00 | $67.71 |
| 2012 | $6.26 | $31.30 | |||
| 2013 | $17.94 | $2.87 | $0.00 | ||
| 2014 | $21.40 | $27.74 | $2.01 | $0.00 | $0.00 |
| 2015 | $12.03 | $31.20 | |||
| 2016 | $16.33 | ||||
| 2017 | $26.23 | ||||
| 2018 | $29.65 | $0.00 | $0.00 | ||
| 2019 | $23.10 | $177.91 | $161.15 | $0.00 | $0.00 |
| 2020 | $39.11 | $35.28 | $190.22 | $0.00 | $0.00 |
| 2021 | $22.14 | $24.48 | $49.04 | $0.00 | $0.00 |
| 2022 | $17.98 | $25.51 | $1.51 | $0.00 | $0.00 |
| 2023 | $27.82 | $25.61 | $0.00 | $0.00 | $0.00 |
| 2024 | $74.89 | $43.14 | $0.00 | $0.00 | $0.00 |
| 2025 | $146.32 | $74.03 | $2.28 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Insmed Incorporated's (INSM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $74.03
- Current price
- $133.26
- AI upside
- -44.45%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5,263.35
+3,849.68% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| INSM | Insmed Incorporated | $133.26 | 31.85B | -44% | +3,850% | — | — | -24.48 | 42.30 | 51.55 | -26.12 | -162.35 | 61.87 | 79.41% | -194.04% | -210.54% | -249.28% | -969.45% | -59.53% | 1.04 | -14.04 | 3.83 | 3.35 | -0.22 | 1508.00% | 6673.00% | 3709.00% | -3.10% | -1.99 | -797.14% | 0.00% | 0.00% | 1.60% | -26.00 | -31.62 | 50.46 | 8.06 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $87.18 | 42.49B | -32% | -61% | -65% | -71% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| GEHC | GE HealthCare Technologie… | $84.27 | 38.41B | +5% | -50% | -83% | -31% | 16.99 | 3.53 | 1.77 | 11.12 | 351.11 | -8.63 | 39.99% | 13.39% | 10.10% | 22.88% | 13.96% | 6.15% | 0.96 | 6.14 | 1.18 | 0.93 | 1.45 | 484.00% | 484.00% | -284.00% | 4.12% | 0.22 | 9.78% | 0.17% | 3.00% | 3.44% | 15.24 | 27.95 | 2.04 | 1.89 |
| HLN | Haleon plc | $11.07 | 49.3B | +256% | -54% | — | -81% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| HUM | Humana Inc. | $190.54 | 22.92B | -18% | +504% | -67% | -8% | 18.99 | 1.28 | 0.17 | 5.17 | — | 2.83 | 14.54% | 1.12% | 0.92% | 6.98% | 6.79% | 2.49% | 0.70 | 2.30 | 2.00 | 1.42 | 2.81 | -140.00% | 1006.00% | -8432.00% | 1.66% | 0.06 | 2.12% | 1.91% | 36.20% | 5.92% | 10.34 | 40.07 | 0.12 | 4.42 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| ONC | BeOne Medicines Ltd. | $316.99 | 33.87B | -9% | +1,119% | -83% | -61% | 119.49 | 7.86 | 6.42 | 49.99 | — | 7.98 | 87.49% | 8.37% | 5.37% | 7.46% | 22.87% | 4.07% | 0.25 | 7.68 | 3.41 | 2.96 | -5.60 | -63742.00% | 4023.00% | -24061.00% | 2.75% | 0.62 | 69.99% | 0.00% | 0.00% | 5.56% | 68.95 | 32.74 | 5.77 | 5.43 |
| RMD | ResMed Inc. | $256.26 | 37.41B | -10% | -40% | -86% | -35% | 28.88 | 6.78 | 7.86 | 20.96 | 77.17 | 16.47 | 59.36% | 32.75% | 27.22% | 25.86% | 25.33% | 18.62% | 0.14 | 133.66 | 3.44 | 2.16 | -0.19 | 3743.00% | 984.00% | 2918.00% | 4.11% | 1.72 | 29.91% | 0.77% | 22.20% | 3.96% | 23.79 | 24.13 | 7.79 | 13.72 |
| TAK | Takeda Pharmaceutical Com… | $18.75 | 59.23B | +21% | -68% | — | -82% | 66.53 | 1.04 | 1.57 | 9.33 | — | -3.55 | 65.51% | 7.48% | 2.36% | 1.52% | 1.87% | 0.74% | 0.65 | 2.49 | 1.01 | 0.45 | 3.41 | -2624.00% | 745.00% | 26347.00% | 11.93% | 0.42 | 7.55% | 4.21% | 280.30% | 8.50% | 32.96 | 13.18 | 2.46 | 1.11 |
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
- CEO
- William H. Lewis
- Employees
- 1.27K
- Beta
- 1.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5,263.35 ÷ $133.26) − 1 = +3,849.68% (DCF, example).